8-K/A: TNF Pharma Enters Crypto Mining with LightSolver Tech

Sentiment:

Strategic Partnership and Acquisition Agreement


TNF Pharmaceuticals, Inc. announces a strategic acquisition of LPU Holdings LLC and an exclusive technology license with LightSolver Ltd. to enter the cryptocurrency mining business.

Capital raiseTNFA will conduct a Concurrent Equity Offering, issuing Series H convertible preferred stock to certain investors for aggregate gross proceeds of at least $7.5 million at a conversion price of $5.00 per share (post reverse stock split).The agreement includes contingent consideration tied to future Equity Offerings by TNFA, with LightSolver and Newcorp's sellers receiving a percentage of proceeds (6.25% of the first $8M, then 5% of proceeds between $8M and $50M).A one-time Milestone Payment in TNFA Common Stock is triggered if aggregate Equity Offering proceeds equal or exceed $50,000,000.

Summary

  • TNF Pharmaceuticals, Inc. (TNFA) has acquired 100% of LPU Holdings LLC (Newcorp), a Delaware limited liability company, to establish a cryptocurrency mining business.
  • Newcorp has simultaneously entered into an exclusive Technology License and Development Agreement with LightSolver Ltd. (LS), an Israeli company, to utilize LS's proprietary laser processing hardware units (LPUs) and technology for cryptocurrency mining applications.
  • LightSolver will perform development work to customize and enhance its technology for crypto mining, for which Newcorp will pay US$8,500,000 in Non-Recurring Engineering (NRE) Fees, paid in installments upon achievement of Development Milestones.
  • As consideration for the acquisition, TNFA will issue Series I Convertible Preferred Stock to Newcorp's previous owners (Sellers), convertible into 747,362 shares of TNFA Common Stock, representing 19.9% of TNFA's common stock on an as-converted basis immediately after issuance.
  • LightSolver will receive a cash payment of the greater of 25% of the proceeds from TNFA's Concurrent Equity Offering or $1,500,000.
  • Newcorp will pay LightSolver a 5% revenue share of its gross revenue derived from cryptocurrency mining operations, machine sales, or related services.
  • Additional contingent consideration (Milestone Payments) includes further cash and equity payments to both Sellers and LightSolver based on future equity offerings, TNFA's market capitalization reaching $100M, $250M, and $500M, and Newcorp achieving $1,000,000 in gross revenue.
  • A Joint Steering Committee (JSC) will be established to oversee the Development Plan, with Newcorp having a deciding vote in case of deadlock on material aspects.
  • LightSolver will place production and assembly documentation, including software source code, into escrow, to be released to Newcorp under specific breach or insolvency conditions for limited maintenance and operation.
  • Newcorp's previous owners have entered into a Stockholder Voting Agreement, committing to vote their shares in favor of TNFA management's recommendations for three years, subject to a 4.9% beneficial ownership limitation.

Sentiment

Score: 7

Explanation: The filing details a significant strategic expansion into a new, high-potential industry with a clear technology partner and structured financial incentives. While the venture into cryptocurrency mining introduces new risks for a pharmaceutical company, the detailed agreements, NRE fees, revenue sharing, and milestone payments suggest a well-thought-out entry strategy. The escrow arrangement and registration rights also provide some safeguards for the new stakeholders.

Positives

  • TNFA gains exclusive access to LightSolver's advanced laser processing technology for cryptocurrency mining, potentially offering high computational performance with minimal energy consumption.
  • The acquisition and licensing agreement provide a clear framework for TNFA's strategic entry into the potentially lucrative digital asset mining sector.
  • LightSolver receives significant NRE fees (US$8,500,000) and a 5% revenue share, providing a stable revenue stream and incentive for successful development.
  • The contingent consideration structure aligns interests, offering additional payments to LightSolver and Newcorp's sellers upon achievement of key financial and market capitalization milestones for TNFA.
  • The escrow arrangement for LightSolver's technology documentation provides Newcorp with a safeguard against potential future support failures or insolvency of LightSolver.

Negatives

  • The Development Plan and Machine Supply Agreement details, including timelines, specific milestones, and minimum purchase commitments, are yet to be mutually agreed upon and attached as exhibits, introducing uncertainty.
  • Newcorp is restricted to using LightSolver's technology solely for cryptocurrency mining, limiting diversification within the technology's potential applications.
  • LightSolver retains all IP rights to the core technology and improvements, with Newcorp only owning specific application layer software innovations, potentially limiting Newcorp's long-term control over its core operational technology.
  • The Stockholder Voting Agreement grants TNFA's management significant voting power over the shares issued to Newcorp's sellers for three years, potentially reducing the influence of these new large shareholders.
  • The Market Cap Warrants are only exercisable if Newcorp completes a strategic transaction with a digital asset company within six months of the Closing Date, adding a condition to a potential future payout.

Risks

  • Failure to mutually agree on the Development Plan or Machine Supply Agreement could lead to termination of the License Agreement or conversion to a non-exclusive license, impacting the business's viability.
  • Newcorp's failure to meet minimum machine purchase commitments or NRE/revenue sharing payments could result in the conversion of the exclusive license to non-exclusive, increasing competition.
  • The success of the cryptocurrency mining business is subject to volatile cryptocurrency market conditions and regulatory changes, which are outside the control of TNFA or LightSolver.
  • The indemnification clauses highlight potential liabilities for both parties related to gross negligence, willful misconduct, and intellectual property infringement.
  • TNFA must obtain stockholder approval for the issuance of shares related to Milestone Payments and Market Cap Warrants, and failure to do so could delay or prevent these issuances.

Future Outlook

The filing outlines a clear strategic direction for TNFA to enter the cryptocurrency mining sector, contingent on the successful development and customization of LightSolver's technology. Future milestones include the finalization of a detailed Development Plan and Machine Supply Agreement, achievement of specific financial and market capitalization targets, and securing stockholder approval for share issuances. The success hinges on the effective collaboration between LightSolver and Newcorp in developing the specialized hardware and software for crypto mining, as well as favorable market conditions in the digital asset space.

Industry Context

This announcement signifies a significant strategic pivot for TNF Pharmaceuticals, Inc., a company traditionally focused on pharmaceuticals, into the high-growth but volatile cryptocurrency mining industry. This move suggests a diversification strategy, potentially leveraging LightSolver's innovative laser technology for energy-efficient and high-performance computational tasks. The entry into digital assets aligns with a broader trend of companies exploring new revenue streams and technological applications, but also exposes TNFA to new market risks and operational challenges distinct from its core pharmaceutical business.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Committee FormationEstablishment of a Joint Steering Committee (JSC) within 30 days of the Effective Date to oversee and coordinate the performance of the Development Plan. Each party appoints 2 representatives, with Newcorp having a deciding vote in case of deadlock on material aspects.Within 30 days of 2025-09-02Enhances oversight and coordination for the critical development phase, but Newcorp's deciding vote grants it significant control over the strategic direction of the Development Work.
Voting AgreementNewcorp's sellers (Stockholders) agree to vote their shares in favor of matters proposed and recommended by TNFA's management for three years, subject to a 4.9% beneficial ownership limitation.2025-09-04Provides TNFA's existing management with stability and control over corporate decisions, mitigating potential dissent from new large shareholders for a defined period.

Stakeholder Impact

  • **Shareholders (TNFA):** Significant strategic shift into a new industry, potentially diversifying revenue streams but also introducing new market and operational risks. Dilution from preferred stock issuance to Newcorp sellers and potential future equity issuances for milestones. Potential for substantial returns if the crypto mining venture is successful.
  • **Shareholders (Newcorp Sellers):** Receive substantial upfront consideration in TNFA preferred stock and potential future milestone payments, aligning their interests with TNFA's success. Subject to a voting agreement for three years.
  • **LightSolver Ltd.:** Secures a significant NRE fee and a long-term revenue sharing agreement, providing capital for development and a pathway to commercialization for its technology in the crypto mining sector. Retains IP rights for other applications.
  • **Employees (TNFA/Newcorp):** Potential for new job creation and skill development in the digital asset space. Newcorp will engage a Cryptocurrency Expert and LightSolver will provide training to Newcorp personnel.
  • **Customers (Newcorp):** Will gain access to LightSolver's proprietary laser processing hardware units (LPUs) for cryptocurrency mining, with Newcorp providing first-tier support.

Next Steps

  • TNF Pharmaceuticals, Inc. will complete a Concurrent Equity Offering of Series H convertible preferred stock.
  • The parties will mutually agree upon and attach a detailed Development Plan as Exhibit A to the License Agreement.
  • A Joint Steering Committee (JSC) will be established within 30 days after the Effective Date to oversee the Development Plan.
  • Initial Supply Terms for Machines will be negotiated and mutually agreed upon within 60 days following the execution of the License Agreement.
  • The parties will negotiate and execute a Machine Supply Agreement prior to the completion of Development Phase 2.
  • LightSolver will perform Development Work to customize and enhance its technology for cryptocurrency mining applications.
  • LightSolver and Newcorp will enter into an escrow agreement within 90 days of the License Agreement's execution, with LightSolver depositing production and assembly documentation.
  • TNF Pharmaceuticals, Inc. will call a stockholder meeting within 60 days of the Closing to seek approval for the issuance of shares related to Milestone Payments and Market Cap Warrants.
  • TNF Pharmaceuticals, Inc. will file an initial Registration Statement on Form S-3 (or S-1) within 30 days of the Closing to cover the resale of Registrable Securities, and additional statements for subsequent Milestone Events.

Key Dates

DateDescription
2025-04-30Binding term sheet between LightSolver, Michael Vasinkevich, and Nadav Kidron (Newcorp Founders) establishing a framework for strategic business collaboration.
2025-05-16Certificate of Formation of LPU Holdings LLC filed with the Delaware Secretary of State.
2025-09-02Effective Date of the Technology License and Development Agreement between LightSolver Ltd. and LPU Holdings LLC.
2025-09-02Date of the Membership Interest Purchase Agreement between LPU Holdings LLC and TNF Pharmaceuticals, Inc.
2025-09-02Expected date for TNF Pharmaceuticals, Inc.'s reverse stock split to take effect.
2025-09-04Date of the Stockholder Voting Agreement between TNF Pharmaceuticals, Inc. and the Stockholders.
2025-09-05Date of the Current Report on Form 8-K/A filing.
2025-10-02Deadline for establishing a Joint Steering Committee (JSC) (within 30 days after the Effective Date).
2025-11-01Deadline for negotiating and mutually agreeing upon Initial Supply Terms for Machines (within 60 days following the execution of the License Agreement).
2025-12-01Deadline for entering into an escrow agreement with a mutually agreed escrow agent (within 90 days following the execution of the License Agreement).
2025-12-01Deadline for TNF Pharmaceuticals, Inc. to call a stockholder meeting to seek approval for the issuance of shares included in Milestone Payments and Market Cap Milestone Payments (within 60 days following the Closing).
2026-03-02Deadline for Newcorp to complete or enter into a strategic transaction or partnership with a digital asset company for the Market Cap Warrants to become exercisable (within six months of the Closing Date).
2028-09-04Expiration Date of the Stockholder Voting Agreement (three years after its date).

Recommendation

buy

This filing details a bold and potentially transformative strategic move for TNF Pharmaceuticals, Inc. by entering the cryptocurrency mining sector with an exclusive license to LightSolver's innovative laser technology. While the pharmaceutical industry faces its own challenges, diversifying into a high-growth, high-margin area like digital asset mining, especially with a technology promising efficiency, could unlock significant shareholder value. The structured NRE fees, revenue sharing, and milestone payments align the interests of all parties, and the acquisition of Newcorp provides a dedicated vehicle for this new venture. The potential for substantial market capitalization growth, as indicated by the milestone payments, suggests a strong upside. Investors should consider this a 'buy' for its long-term growth potential, despite the inherent risks associated with entering a new, volatile market.

Keywords

Cryptocurrency Mining, Laser Processing Units, Technology License, Acquisition, SEC Filing, Strategic Partnership, Intellectual Property, Development Agreement, Revenue Sharing, Market Capitalization Milestones, Preferred Stock, Warrants, Corporate Governance, Risk Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.